Person: SOYSAL, PINAR
99 results
Search Results
Now showing 1 - 10 of 99
Publication Metadata only Decreased Basal Metabolic Rate Can Be an Objective Marker for Sarcopenia and Frailty in Older Males.(2019-01-01) Soysal, PINAR; Ates, Bulut; YAVUZ, I; SOYSAL, PINARPublication Metadata only Telomere length and health outcomes: An umbrella review of systematic reviews and meta-analyses of observational studies.(2019-05-01) SMITH, L; LOPEZ-SANCHEZ, GF; FIRTH, J; KOYANAGI, A; ROBERTS, J; WILLEIT, P; WALDHOER, T; LOOSEMORE, M; ABBS, AD; JOHNSTONE, J; YANG, L; VERONESE, N; Soysal, PINAR; LUCHINI, C; DEMURTAS, J; STUBBS, B; HAMER, M; NOTTEGAR, A; LAWLOR, RT; SOYSAL, PINARPublication Metadata only Which Cholinesterase Inhibitor is the Safest for the Heart in Elderly Patients With Alzheimer-s Disease?(2012-05-01T00:00:00Z) ISIK, Ahmet Turan; BOZOGLU, Ergun; YAY, Adnan; Soysal, PINAR; ATESKAN, Umit; SOYSAL, PINARObjective: Cholinesterase inhibitors (ChEIs) are widely used for the treatment of Alzheimer-s disease (AD); however, their cholinergic side effects on the cardiovascular system are still unclear. In this study, we aimed to examine the side effects caused by donepezil, rivastigmine, and galantamine on cardiac rhythm and postural blood pressure changes in elderly patients with AD. Methods: Of 204 consecutive elderly patients who were newly diagnosed with AD, 162 were enrolled and underwent comprehensive geriatric assessments. The electrocardiographs (ECGs) and blood pressures were recorded at the baseline and 4 weeks after the dose of 10 mg/d of donepezil, 10 cm2/d of rivastigmine, and 24 mg/d of galantamine. Results: There were no changes relative to the baseline in any of the ECG parameters or arterial blood pressure with any of the administered ChEIs. Conclusion: It was demonstrated that none of the 3 ChEIs were associated with increased negative chronotropic, arrhythmogenic, and hypotensive effects for the elderly patients with AD.Publication Metadata only Prevalence of depressive symptoms in elderly cancer patients receiving chemotherapy and influencing factors.(2018-09-01T00:00:00Z) ATAG, E; MUTLAY, F; Soysal, PINAR; SEMIZ, HS; KAZAZ, SN; KESER, M; ELLIDOKUZ, H; KARAOGLU, A; SOYSAL, PINARPublication Metadata only Corrigendum to -Inflammation and frailty in the elderly: A systematic review and meta-analysis- [Ageing Res Rev. 31 (2016) 1-8].(2017-05-01T00:00:00Z) Soysal, PINAR; STUBBS, B; LUCATO, P; LUCHINI, C; SOLMI, M; PELUSO, R; SERGI, G; ISIK, AT; MANZATO, E; MAGGI, S; MAGGIO, M; PRINA, AM; COSCO, TD; WU, YT; VERONESE, N; SOYSAL, PINARPublication Metadata only Uric acid may be protective against cognitive impairment in older adults, but only in those without cardiovascular risk factors.(2017-03-01T00:00:00Z) TUVEN, B; Soysal, PINAR; UNUTMAZ, G; KAYA, D; ISIK, AT; SOYSAL, PINARPublication Metadata only Vitamin B<sub>12</sub> deficiency can be a cause of acute reversible parkinsonism and cognitive impairment in older adults.(2018-04-01T00:00:00Z) Soysal, PINAR; Turan, Isik; SOYSAL, PINARPublication Open Access Validity of the Kihon Checklist for evaluating frailty status in Turkish older adults.(2019-07-01) Isik, AT; Dokuzlar, O; Esenkaya, ME; Smith, L; Soysal, PINAR; SOYSAL, PINARPublication Metadata only Validity and Reliability of Rapid Cognitive Screening Test for Turkish Older Adults.(2019-01-01) Soysal, PINAR; Koc, Okudur; ISIK, AT; USAREL, C; DOKUZLAR, O; SOYSAL, PINARPublication Open Access Orthostatic hypotension and health outcomes: an umbrella review of observational studies(2019-11-07) Veronese, Nicola; Smith, Lee; Torbahn, Gabriel; Jackson, Sarah E.; Yang, Lin; SOYSAL, PINAR; Rivasi, Giulia; Rafanelli, Martina; Petrovic, Mirko; Maggi, Stefania; Isik, Ahmet Turan; Demurtas, Jacopo; SOYSAL, PINARPurpose Orthostatic hypotension (OH) is associated with older age and many negative clinical outcomes in geriatric practice. We aimed to capture the breadth of outcomes that have been associated with the presence of OH and systematically assess the quality, strength and credibility of these associations using an umbrella review with integrated meta-analyses. Methods We systematically searched several major databases from their commencements through to 16th May 2019 for meta-analyses of observational studies of OH and any health-related outcome. We used these metrics to categorize the strength of evidence of significant outcomes (p < 0.05) from class I (convincing) to class IV (weak), according to the pre-established criteria. Results From 975 abstracts, seven meta-analyses of 12 outcomes were included. For each outcome, the median number of studies was four, and the median number of participants was 46,493, with a median of 3630 incident cases. There was suggestive (class III) evidence that OH was associated with significantly higher risk of coronary heart disease (HR = 1.32, 95% CI 1.12-1.56), stroke (HR = 1.22, 95% CI 1.08-1.38), congestive heart failure (HR = 1.30, 95% CI 1.09-1.55), all-cause mortality (RR = 1.50, 95% CI 1.24-1.81), falls (OR = 1.84, 95% CI 1.39-2.44), and dementia (HR = 1.22, 95% CI 1.11-1.35). Conclusion The current evidence base indicates that OH is significantly associated with a range of adverse cardiovascular, cognitive, and mortality outcomes in older people, although the strength of this evidence remains only suggestive. Further research in larger samples and with lower risk of bias is required to build a fuller picture of the impact of OH on health.